2243079-26-5

Mice are implanted bilaterally with B16-Ova, and IACS-8779 (compound 1a) is administered at 10 μg dose with three intra-tumoral injections, on one flank only, on day 6, 9, 12 post implantation. While IACS-8779 shows comparable antitumor activity on the injected flank, IACS-8779 achieves superior regression on the untreated tumor in the contralateral flank, suggesting a more significant systemic immune response compared to the benchmark analogs. Treatment with IACS-8779 also results in a higher number of mice cured of both tumors compared to benchmarks^[1].